Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMO II: Paricalcitol Injection for Cardiac Morbidity in CKD Stage 5
NCT00616902Phase 3Terminated
- Sponsor
- Abbott Laboratories
- Start
- Jan 2009
- Primary completion
- May 2009
- Modality
- Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 3 trial of paricalcitol in left ventricular hypertrophy (LVH), sponsored by Abbott Laboratories. Started Jan 2009; status: terminated.
02
Drugs
paricalcitol
03
Conditions
left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on NCT00616902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00616902.